Circ_0007534 promotes cholangiocarcinoma stemness and resistance to anoikis through DDX3X-mediated positive feedback regulation of parental gene DDX42
Cellular Signalling · 2024
DOI: 10.1016/j.cellsig.2024.111141 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cellular Signalling, 2024. Verfasst von Sidi Liu und 8 weiteren Autor:innen. Beteiligte Einrichtung: General Surgery Department, The 2nd Affiliated Hospital of Harbin Medical University, 148 Baojian Street, Harbin 150086, Heilongjiang Province, China. Hauptthemen laut MEDLINE: MicroRNAs, Cholangiocarcinoma, Bile Duct Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: Heilongjiang Postdoctoral Science Foundation.
Abstract (Originalsprache)
Cholangiocarcinoma (CCA) is a malignancy with an extremely poor prognosis, and much remains unknown about its pathogenesis and treatment modalities. Circular RNA (circRNA) has been proven to play regulatory roles in various tumorigenesis, yet its potential function and mechanism in cholangiocarcinoma require further investigation. This study is the first to identify the aberrant expression and functional role of a novel circRNA, circ_0007534, derived from the DDX42 gene, in cholangiocarcinoma. Compared to the normal control group, the expression of circ_0007534 was significantly elevated in the tissues and cells with CCA and that high expression correlated with lymph node invasion and poor prognosis. Functional experiments indicated that downregulating circ_0007534 markedly inhibited the proliferation, migration, invasion, stemness, and anti-anoikis ability of CCA cells, as well as the tumor growth and liver and lung metastasis in nude mice. Mechanistic studies revealed that DDX42, as the parent gene of circ_0007534, can mutually regulate each other's expression. Predominantly located in the cytoplasm, circ_0007534 can form a complex with the RNA-binding protein DDX3X, which enhances the stability of DDX42 mRNA, thereby upregulating the expression of DDX42. This creates a positive feedback loop among the three, collectively promoting the progression of cholangiocarcinoma. In conclusion, this study sheds light on the pivotal role and molecular mechanism of circ_0007534 in the development of CCA, offering potential new targets for early diagnosis and treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- General Surgery Department, The 2nd Affiliated Hospital of Harbin Medical University, 148 Baojian Street, Harbin 150086, Heilongjiang Province, China.
- General Surgery Department, The 2nd Affiliated Hospital of Harbin Medical University, 148 Baojian Street, Harbin 150086, Heilongjiang Province, China. Electronic address: zhongxiangyu@hrbmu.edu.com.
- General Surgery Department, The 2nd Affiliated Hospital of Harbin Medical University, 148 Baojian Street, Harbin 150086, Heilongjiang Province, China. Electronic address: xmjiang@hrbmu.edu.cn.
Förderung
- Heilongjiang Postdoctoral Science Foundation
Zitieren
APA
Liu, S., Guan, C., Sha, X., Gao, X., Zou, X., Yang, C., Zhang, X., Zhong, X., & Jiang, X. (2024). Circ_0007534 promotes cholangiocarcinoma stemness and resistance to anoikis through DDX3X-mediated positive feedback regulation of parental gene DDX42. Cellular Signalling. https://doi.org/10.1016/j.cellsig.2024.111141
Vancouver
Liu S, Guan C, Sha X, Gao X, Zou X, Yang C, et al. Circ_0007534 promotes cholangiocarcinoma stemness and resistance to anoikis through DDX3X-mediated positive feedback regulation of parental gene DDX42. Cellular Signalling. 2024. doi:10.1016/j.cellsig.2024.111141
BibTeX
@article{Liu2024,
author = {Liu, Sidi and Guan, Canghai and Sha, Xiangjun and Gao, Xin and Zou, Xinlei and Yang, Chengru and Zhang, Xinmiao and Zhong, Xiangyu and Jiang, Xingming},
title = {Circ_0007534 promotes cholangiocarcinoma stemness and resistance to anoikis through DDX3X-mediated positive feedback regulation of parental gene DDX42},
journal = {Cellular Signalling},
year = {2024},
doi = {10.1016/j.cellsig.2024.111141}
}
EUVIMED